Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer

Future Oncology

Volumn 10, Issue 7, 2014, Pages 1255-1275

  Khan, Meaghan L ^a   Halfdanarson, Thorvardur R ^a   Borad, Mitesh J ^a  

^a MAYO CLINIC   (United States)

Author keywords

immunotherapy; oncolytic viral; pancreatic cancer; vaccine therapy

Indexed keywords

ADENOVIRUS VACCINE; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLIN G1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GOLNERMINOGENE PRADENOVEC; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOLOGIC AGENT; INTERLEUKIN 10; INTERLEUKIN 4; MESOTHELIN; ONCOLYTIC VIRUS;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; DNA DAMAGE; HUMAN; IMMUNE RESPONSE; IMMUNITY; LYMPHOCYTE PROLIFERATION; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REOVIRUS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TANDEM REPEAT; TUMOR MICROENVIRONMENT; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION; ADENOCARCINOMA; ANIMAL; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ADENOCARCINOMA; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS;

EID: 84903198479     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.277     Document Type: Review

References (163)

1. Surveillance, Epidemiology, and End Results Program. http://seer.cancer. gov
2. Bakkevold KE, Kambestad B. Long-term survival following radical and palliative treatments with carcinoma of the pancreas and papilla of Vater: the prognostic factors infuencing the long-term results. A prospective multicentre study. Eur. J. Surg. Oncol. 19 (2), 147-161 (1993).
3. Riall TS, Cameron JL, Lillemoe KD et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6-to 10-year follow up. Surgery 140(5), 764-772 (2006).
4. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical beneft with gemcitabine as frst-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15 (6), 2403-2413 (1997).
5. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25 (15), 1960-1966 (2007).
6. Von Hoff DD, Ervin TJ, Arena FP et al. Randomized Phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J. Clin. Oncol. 30(Suppl. 34), Abstract LBA148 (2012).
7. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX verses gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817-1825 (2011).
8. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
9. Gjertsen MK, Bakka A, Breivik J et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation. Lancet 346(8987), 1399-1400 (1995).
10. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67(19), 9518-9527 (2007).
11. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreatic or breast adenocarcinoma. J. Immunol. 169(5), 2756-2761 (2002).
12. + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12(18), 5423-5434 (2006).
13. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010)
14. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
15. Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines for pancreatic cancer. Cancer J. 18(6), 642-652 (2012).
16. Torres MP, Chakraborty S, Souchek J, Batra SK. Mucin-based targeted pancreatic cancer therapy. Curr. Pharm. Des. 18(17), 2472-2481 (2012).
17. Yu YA, Galanis C, Woo Y et al. Regression of human pancreatic tumor xenografts in mice after a single injection of recombinant vaccine virus GLV-1h68. Mol. Cancer Ther. 8, 141-151 (2009).
18. Maitra R, Ghalib MH, Goel S. Reovirus: a targeted therapeutic-progress and potential. Mol. Cancer Res. 10, 1514-1525 (2012).
19. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell carcinoma associated with enteritis and hypophysitis. J. Immunother. 30(8), 825-830 (2007).
20. Small EJ, Tchekmedyian S, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone refractory prostate cancer. Clin. Cancer Res. 13, 1810-1815 (2007).
21. Theoret MR, Arlen PM, Pazdur M, Dahut WL, Schlom J, Gulley JL. A Phase I trial of an enhanced prostate-specifc antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin. Genitourin. Cancer 5(5), 347-350 (2007).
22. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90, 297-339 (2006).
23. Royal RE, Levy C, Turner K et al. A Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33(8), 828-833 (2010).
24. Nomi T, Sho M, Akahori T et al. Clinical signifcance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13(7), 2151-2157 (2007).
25. Okudaira K, Hokari R, Tsuzuki Y et al. Blockade of B7-H1 or B7-DC induces an antitumor effect in a mouse pancreatic cancer model. Int. J. Oncol. 35(4), 741-749 (2009).
26. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
27. Tykodi SS, Brahmer JR, Hwu W et al. PD-1/PD-L1 pathway as a target for cancer immunotherapy: safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. J. Clin. Oncol. 30(Suppl. 15), Abstract 2510 (2012).
28. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000).
29. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2(3), 261-268 (2001).
30. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).
31. Brown JA, Dorfman DM, Ma FR et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170 (3), 1257-1266 (2003).
32. Razzaque S, Ashraf N, Julio C et al. Expression of programmed death ligand 1 (PD-L1) in malignant and nonmalignant pancreatic tissue. J. Clin. Oncol. 31(Suppl. 4), Abstract 215 (2013).
33. Geng L, Huang D, Liu J et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J. Cancer Res. Clin. Oncol. 134(9), 1021-1027 (2008).
34. Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical signifcance of B7-H1 expressions in pancreatic carcinoma. World J. Surg. 34(5), 1059-1065 (2010).
35. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28 (19), 3167-3175 (2010).
36. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012)
37. Gemcitabine and CT-011 for Resected Pancreatic Cancer. http://clinicaltrials.gov/show/NCT01313416
38. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specifc immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63(1), 298-304 (1996).
39. Pecher G, Häring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol. Immunother. 51, 669-673 (2002).
40. Ramanathan RK, Lee KM, McKolanis J et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54(3), 254-264 (2005).
41. Kubuschok B, Pfreundschuh M, Breit R et al. Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial. Hum. Gene Ther. 23(12), 1224-1236 (2012).
42. Gjertsen MK, Buanes T, Rosseland AR et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer 92(3), 441-450 (2001).
43. Toubaji A, Achtar M, Provenzano M et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol. Immunother. 57(9), 1413-1420 (2008).
44. Le DT, Brockstedt DG, Nir-Paz R et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin. Cancer Res. 18(3), 858-868 (2012).
45. Bernhardt SL, Gjertsen MK, Trachsel S et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating Phase I/II study. Br. J. Cancer 95(11), 1474-1482 (2006).
46. Jaffee EM, Hruban RH, Biedrzycki B et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol. 19(1), 145-156 (2001).
47. Lutz E, Yeo CJ, Lillemoe KD et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, effcacy, and immune activation. Ann. Surg. 253(2), 328-335 (2011).
48. Laheru D, Lutz E, Burke J et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 14(5), 1455-1463 (2008).
49. Oyama Y, Talamonti M, Mulcahy M et al. A Phase I/II study of an antitumor vaccination using ct(1, 3) galactosyltransferase expressing allogeneic tumor cells in pancreatic cancer. J. Clin. Oncol. 25(Suppl. 185), Abstract 13512 (2007).
50. Hardacre JM, Mulcahy MF, Talamonti M et al. Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survivial: preliminary analysis of Phase II data. J. Clin. Oncol. 28(Suppl. 15), Abstract 4059 (2010).
51. Gendler SJ, Spicer A P, Lalani EN et al. Structure and biology of a carcinoma-associated mucin, MUC1. Am. Rev. Respir. Dis. 144(3), S42-S47 (1991).
52. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 4(1), 45-60 (2004).
53. Kohlgraf KG, Gawron AJ, Higashi M et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 63(16), 5011-5020 (2003).
54. Tsutsumida H, Swanson BJ, Singh PK et al. RNA interface suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin. Cancer Res. 12(10), 2976-2987 (2006).
55. Besmer DM, Curry JM, Roy LD et al. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res. 71(13), 4432-4442 (2011).
56. Mukherjee P, Ginardi AR, Madsen CS et al. MUC1-specifc CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj. J. 18, 931-942 (2001).
57. Rong Y, Jin D, Wu W et al. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 9, 191 (2009).
58. Rong Y, Qin X, Jin D et al. A Phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin. Exp. Med. 12(3), 173-180 (2012).
59. Wu WC, Jin DY, Lou WH, Wang DS, Qin XY. Induction of antigen-specifc CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer. J. Cancer Res. Clin. Oncol. 136(12), 1861-1868 (2010).
60. Bafna S, Kaur S, Momi N, Batra SK. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br. J. Cancer 101(7), 1155-1161 (2009).
61. Mimeault M, Johansson SL, Senapati S, Momi N, Chakraborty S, Batra SK. MUC 4 down-regulates reverse chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett. 295(1), 69-84 (2010).
62. Hruban RH, van Mansfeld AD, Offerhaus GJ et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. Am. J. Pathol. 143(2), 545-554 (1993).
63. Brembeck FH, Schreiber FS, Deramaudt TB et al. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infltration and gastric mucous neck hyperplasia in transgenic mice. Cancer Res. 63(9), 2005-2009 (2003).
64. Carbone DP, Ciernik IF, Kelley MJ et al. Immunization with mutant p53-and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J. Clin. Oncol. 23(22), 5099-5107 (2005).
65. Hsieh CL, Chen DS, Hwang LH. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum. Gene Ther. 11(5), 681-692 (2000).
66. Wedén S, Klemp M, Gladhaug IP et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int. J. Cancer 128(5), 1120-1128 (2011).
67. +-T-cell potency during bacterial infection. Infect. Immun. 74(11), 6387-6397 (2006).
68. Safey SA, Cluff CW, Marshall NE, Ziegler HK. Role of listeriolysin-O (LLO) in the T-lymphocyte response to infection with Listeria monocytogenes. Identifcation of T cell epitopes of LLO. J. Immunol. 146 (10), 3604-3616 (1991).
69. Reinicke AT, Omilusik KD, Basha G, Jefferies WA. Dendritic cell cross-priming is essential for immune responses to Listeria monocytogenes. PLoS ONE 4 (10), 7210 (2009).
70. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF, Hohmann EL. Safety and shedding of an attenuated strain for Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70(7), 3592-3601 (2002).
71. Johnson PV, Blair BM, Zeller S, Kotton CN, Hohmann EL. Attenuated Listeria monocytogenes vaccine vectors expressing infuenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers. Microbiol. Immunol. 55(5), 304-317 (2011).
72. Singh R, Dominiecki ME, Jaffee EM, Paterson Y. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol. 175(6), 3663-3673 (2005).
73. Argani P, Iacobuzio-Donahue C, Ryu B et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identifcation of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7(12), 3862-3868 (2001).
74. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 10, 3937-3942 (2004).
75. Yoshimura K, Laird LS, Chia CY et al. Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastasis and is strongly enhanced by depletion of regulatory T cells. Cancer Res. 67(20), 10058-10066 (2007)
76. Safety and Effcacy of Listeria and GVAX in Pancreatic Cancer. http://clinicaltrials.gov/show/NCT01417000
77. Vasef MA, Ross JS, Cohen MB. Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Am. J. Clin. Path. 112(1 Suppl. 1), 68-75 (1999).
78. Gunturu KS, Rossi GR, Saif MW. Immunotherapy updates in pancreatic cancer: are we there yet? Ther. Adv. Med. Oncol. 5(1), 81-89 (2013).
79. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int. Rev. Immunol. 25, 321-352 (2006).
80. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264(5161), 961-965 (1994).
81. Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas. http://clinicaltrials.gov/show/NCT01595321
82. Le DT, Lutz E, Huang L et al. Phase 1b study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer. J. Clin. Oncol. 30(Suppl. 4), Abstract 211 (2012).
83. Rother R P, Squinto SP. The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable. Cell 86(2), 185-188 (1996).
84. Mandell RB, Flick R, Staplin WR et al. The αGal HyperAcute Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade. Zoonoses 56, 391-406 (2009).
85. Unfer RC, Hellrung D, Link CJ Jr. Immunity to the alpha(1, 3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1, 3)galactosyl transferase: a novel suicide gene for cancer therapy. Cancer Res. 63(5), 987-993 (2003).
86. Rossi GR, Mautino MR, Unfer RC, Seregina TM, Vahanian N, Link CJ. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1, 3)-galactosyl epitopes. Cancer Res. 65(22), 10555-10561 (2005)
87. Immunotherapy Study for Surgically Resected Pancreatic Cancer. http://clinicaltrials.gov/ct2/show/NCT01072981?term=NCT01072981&rank=1
88. Moon EK, Carpenito C, Sun J et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specifc chimeric antibody receptor. Clin. Cancer Res. 17(14), 4719-4730 (2011).
89. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin. Biol. Ther. 11 (7), 855-873 (2011)
90. June CH. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 117(5), 1204-1212 (2007).
91. Wilkie S, Burbridge SE, Chiapero-Stanke L et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285(33), 25538-25544 (2010).
92. Carpenito C, Milone MC, Hassan R et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106(9), 3360-3365 (2009).
93. Zhao Y, Moon E, Carpenito C et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70(22), 9053-9061 (2010).
94. Li M, Bharadwaj U, Zhang R et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol. Cancer Ther. 7(2), 286-296 (2008)
95. An Effcacy Study of MORAb-009 in Subjects With Pancreatic Cancer. http://clinicaltrials.gov/show/NCT00570713
96. Autologous Redirected RNA Meso-CIR T Cells. http://clinicaltrials.gov/ ct2/show/NCT01355965?term=NCT01355965&rank=1
97. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol. Cancer Ther. 11(3), 517-525 (2012).
98. Maliar A, Servais C, Waks T et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 143(5), 1375-1384 (2012).
99. Till BG, Jensen MC, Wang J et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using a genetically modifed autologous CD20-specifc T-cells. Blood 112(6), 2261-2271 (2008).
100. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J. Immunol. Methods 248, 67-76 (2001).
101. Wilkie S, Picco G, Foster J et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 180(7), 4901-4909 (2008).
102. van Kooten C, Banchereau J. CD-40-CD-40 ligand. J. Leukoc. Biol. 67(1), 2-17 (2000).
103. Diehl L, den Boer AT, Schoenberger SP et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments antitumor vaccine effcacy. Nat. Med. 5(7), 774-779 (1999).
104. (-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl Acad. Sci. USA 99(8), 5561-5566 (2002).
105. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393(6684), 480-483 (1998).
106. He S, Zhao H, Fei M et al. Expression of the co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro. Oncol. Rep. 28(1), 262-268 (2012).
107. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show effcacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612-1616 (2011).
108. Nelson NJ. Viruses and cancer. J. Natl Cancer Inst. 91(20), 1709 (1999).
109. Russell SJ, Peng K W. Viruses as anticancer drugs. Trends Pharmacol. Sci. 28(7), 326-333 (2007).
110. Murphy AM, Besmer DM, Moerdyk-Schauwecker M et al. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J. Virol. 86(6), 3073-3087 (2012).
111. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specifc defects in innate immune signaling pathways. Expert Opin. Biol. Ther. 9(9), 1163-1176 (2009).
112. Motoi F, Sunamura M, Ding L et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum. Gene Ther. 11(2), 223-235 (2000).
113. Mulvihill S, Warren R, Venook A et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther. 8(4), 308-315 (2001).
114. Hecht JR, Bedford R, Abbruzzese JL et al. A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9(2), 555-561 (2003).
115. Etoh T, Himeno Y, Matsumoto T et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin. Cancer Res. 9(3), 1218-1223 (2003).
116. Himeno Y, Etoh T, Matsumoto T, Ohta M, Nishizono A, Kitano S. Effcacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immnocompetent models. Int. J. Oncol. 27, 901-906 (2005)
117. A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma. http://clinicaltrials.gov/show/NCT00998322
118. Haddad D, Chen N, Zhang Q et al. A novel genetically modifed oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers. Ann. Surg. Oncol 19(Suppl. 3), S665-S674 (2012).
119. Kasuya H, Takeda S, Nomoto S, Nakao A. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther. 12(9), 725-736 (2005).
120. Sabin AB. Reoviruses. A new group of respiratory and enteric viruses formerly classifed as ECHO type 10 is described. Science 130(3386), 1387-1389 (1959).
121. Van Den Wollenberg DJ, Van Den Hengel SK, Dautzenberg IJ, Kranenburg O, Hoeben RC. Modifcation of mammalian reoviruses for use as oncolytic agents. Expert Opin. Biol. Ther. 9 (12), 1509-1520 (2009).
122. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO 17(12), 3351-3362 (1998).
123. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 282(5392), 1332-1334 (1998).
124. Min HJ, Koh SS, Cho IR et al. Inhibition of GSK-3beta enhances reovirus-induced apoptosis in colon cancer cells. Int. J. Oncol. 35, 617-624 (2009).
125. Wilcox ME, Yang W, Senger D et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J. Natl Cancer Inst. 93, 903-912 (2001).
126. Norman KL, Coffey MC, Hirasawa K et al. Reovirus oncolysis of human breast cancer. Hum. Gene Ther. 13, 641-652 (2002).
127. Shmulevitz M, Marcato P, Lee PW. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 24, 7720-7728 (2005).
128. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 62, 1696-1701 (2002).
129. Morris DG, Forsyth PA, Paterson AH et al. A Phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confrmed malignancies. Proc. Am. Soc. Clin. Oncol. 21, Abstract 92 (2002).
130. Harrington KJ, Karapanagiotou EM, Roulstone V et al. Two-stage Phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin. Cancer Res. 16, 3067-3077 (2010).
131. Saunders M, Anthoney A, Coffey M et al. Results of a Phase II study to evaluate the biological effects of intratumoral (ITu) Reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J. Clin. Oncol. 27, Abstract e14514 (2009).
132. Twigger K, Vidal L, White CL et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin. Cancer Res. 14, 912-923 (2008).
133. Wadler S, Yu B, Lane M, Klampfer L et al. The oncolytic reovirus, Reolysin augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT116. Eur. J. Cancer Supplements 8, 135 (2004)
134. Viral Therapy in Treating Patient With Liver Cancer. http:// clinicaltrials.gov/show/NCT01628640
135. Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type 1 interferon signaling. Virology 436(1), 221-234 (2013).
136. Seth P. Vector-mediated cancer gene therapy. Cancer Biol. Ther. 4(5), 512-517 (2005).
137. Kuroki M, Kuroki M, Shibaguchi H, Hachimine K, Kinugasa T, Badran A. Tumor-targeting of viral vectors for cancer gene therapy by using antibodies or their genes against tumor-associated antigens. Anticancer Res. 24(5), 3373-3377 (2004).
138. Gordon EM, Cornelio GH, Lorenzo CC 3rd et al. First clinical experience using a pathotropic injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int. J. Oncol. 24(1), 177-185 (2004).
139. Gordon EM, Lopez FF, Cornelio GH et al. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience. Int. J. Oncol. 29(5), 1053-1064 (2006).
140. Galanis E, Carlson SK, Foster NR et al. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construc (Rexin-G) in patients with advanced pancreatic cancer. Mol. Ther. 16(5), 979-984 (2008).
141. Chawla SP, Chua VS, Fernandez L et al. Advanced Phase I/II studies of targeted gene deliver in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol. Ther. 18(2), 435-441 (2010).
142. Schwartz JE, Scuderi P, Wiggins C, Rudolph A, Hersh EM. A Phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy 1(3), 207-214 (1989).
143. Hecht JR, Farrell JJ, Senzer N et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fuorouracil and radiotherapy for frst-line treatment of locally advanced pancreatic cancer: a Phase I/II study. Gastrointest. Endosc. 75(2), 332-338 (2012).
144. Herman JM, Wild AT, Wang H et al. Randomized Phase III multi-institutional study of TNFerade biologic with fuorouracil and radiotherapy for locally advanced pancreatic cancer: fnal results. J. Clin. Oncol. 31(7), 886-894 (2013).
145. Hall FL, Liu L, Zhu NL et al. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum. Gene Ther. 11(7), 983-993 (2000).
146. Swanton C. Cell-cycle targeted therapies. Lancet 5, 27-36 (2004).
147. Hung G, Skotzko MJ, Chang M et al. Intratumoral injection of an antisense cyclin G1 retroviral vector inhibits growth of undifferentiated carcinoma xenografts in nude mice. Int. J. Pediatr. Hematol. Oncol. 4, 317-325 (1997).
148. Gordon EM, Liu PX, Chen ZH et al. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res. 60(13), 3343-3347 (2000).
149. US FDA. Orphan Drug Designations and Approvals. www.accessdata.fda.gov/ scripts/opdlisting/oopd/OOPD-Results-2.cfm
150. Balkwell FR, Lee A, Aldam G et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferon. Cancer Res. 46, 3990-3993 (1996).
151. Asher A, Mule JJ, Reichert CM et al. Studies on the antitumor effcacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. 138, 963-974 (1987).
152. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A Phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J. Clin. Oncol. 6(8), 1328-1334 (1988).
153. Kurzrock R, Feinberg B, Talpaz M, Saks S, Gutterman JU. Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients. J. Interferon Res. 9(4), 435-444 (1989).
154. Hallahan DE, Vokes EE, Rubin SJ et al. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J. Sci. Am. 1(3), 204-209 (1995).
155. Rasmussen H, Rasmussen C, Lempicki M et al. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther. 9(11), 951-957 (2002).
156. Hallahan DE, Beckett MA, Kufe D, Weichselbaum RR. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 19(1), 69-74 (1990).
157. Hallahan DE, Mauceri HJ, Seung LP et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med. 1(8), 786-791 (1995).
158. Marr RA, Addison CL, Snider D, Muller WJ, Gauldie J, Graham FL. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF-alpha. Gene Ther. 4(11), 1181-1188 (1997).
159. Marr RA, Hitt M, Muller WJ, Gauldie J, Graham FL. Tumor therapy in mice using adenovirus vectors expressing human TNFa. Int. J. Oncol. 12(3), 509-515 (1998).
160. Seiwert TY, Darga T, Haraf D et al. A Phase I dose escalation study of Ad GV.EGR. TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann. Oncol. 24(3), 769-776 (2013).
161. Chang KJ, Reid T, Senzer N et al. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. Gastrointest. Endosc. 75 (6), 1139-1146 (2012).
162. Citrin D, Camphausen K, Wood BJ et al. A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology 79, 382-388 (2010).
163. Senzer N, Mani S, Rosemurgy A et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a Phase 1 study in patients with solid tumors. J. Clin. Oncol. 22(4), 592-601 (2004).